• ISB 1442 is a First-In-Class 2+1 Biparatopic Bispecific BEAT^® 2.0 Antibody Targeting CD38 and CD47


• Data from Preclinical Models Suggest Higher Potency and Tumor Growth Inhibition for ISB 1442 Relative to Daratumumab


• Enrollment in the First-in-Human ISB 1442 Trial is Expected to Start in Mid-2022

NEW YORK, NY, December 11, 2021 – Ichnos Sciences Inc., a global biotechnology company developing innovative biologics in oncology, today presented preclinical data that support the potential for ISB 1442, a first-in-class 2+1 biparatopic bispecific antibody that targets both CD38 and CD47, as a treatment for relapsed/refractory multiple myeloma and other CD38+ hematological malignancies. The data were presented today by Stefano Sammicheli, Ph.D., Director of Innate Cell Engagers, during an oral session at the 63^rd American Society of Hematology (ASH) Annual Meeting.

More information